Login to Your Account



IN THE CLINIC NEWS
Orion Corp. and Bayer Healthcare AG, part of Bayer AG, have begun to enroll patients in a phase III trial of ODM-201, an oral androgen receptor (AR) inhibitor the companies are co-developing to treat castration-resistant prostate cancer (CPRC).
LONDON – After surviving one phase III failure, the plug has finally been pulled on tecemotide when it became clear that the cancer vaccine was going to fail a phase II lung cancer study in Japan.
Shares of Receptos Inc. (NASDAQ:RCPT) spiked 20 percent last week, hitting a 52-week high of $61.13 on Thursday, after the abstract was posted for Saturday's late-breaker podium presentation at MS Boston 2014 of the complete dataset from the phase II portion of the company's phase II/III RADIANCE trial of RPC1063 in relapsing multiple sclerosis (RMS).
More IN THE CLINIC Headlines

Cast Your Vote

Has biotech’s bubble burst?: